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ABSTRACT
Objective To evaluate the performance of the QRISK2
score for predicting 10-year cardiovascular disease in an
independent UK cohort of patients from general practice
records and to compare it with the NICE version of the
Framingham equation and QRISK1.
Design Prospective cohort study to validate a
cardiovascular risk score.
Setting 365 practices from United Kingdom contributing
to The Health Improvement Network (THIN) database.
Participants 1.58 million patients registered with a
general practice between 1 January 1993 and 20 June
2008, aged 35-74 years (9.4 million person years) with
71465 cardiovascular events.
MainoutcomemeasuresFirstdiagnosisofcardiovascular
disease (myocardial infarction, angina, coronary heart
disease,stroke,andtransientischaemicstroke)recorded
in general practice records.
ResultsQRISK2offeredimprovedpredictionofapatient’s
10-year risk of cardiovascular disease over the NICE
version of the Framingham equation. Discrimination and
calibration statistics were better with QRISK2. QRISK2
explained 33% of the variation in men and 40% for
women,comparedwith29%and34%respectivelyforthe
NICE Framingham and 32% and 38% respectively for
QRISK1. The incidence rate of cardiovascular events (per
1000personyears)amongmeninthehighriskgroupwas
27.8 (95% CI 27.4 to 28.2) with QRISK2, 21.9 (21.6 to
22.2)withNICEFramingham,and24.8(22.8to26.9)with
QRISK1. Similarly, the incidence rate of cardiovascular
events(per1000personyears)amongwomenin thehigh
risk group was 24.3 (23.8 to 24.9) with QRISK2, 20.6
(20.1 to 21.0) with NICE Framingham, and 21.8 (18.9 to
24.6) with QRISK1.
ConclusionsQRISK2ismoreaccurateinidentifyingahigh
risk population for cardiovascular disease in the United
Kingdom than the NICE version of the Framingham
equation. Differences in performance between QRISK2
and QRISK1 were marginal.
INTRODUCTION
Cardiovascular disease is an important health concern
globally, with just under a third of all deaths attributed
to cardiovascular disease in 2004 (www.who.int, fact
sheet No 317). In the United Kingdom, there are
almost 200000 deaths each year relating to diseases
of the heart and circulatory system, with more than
one in three deaths associated with cardiovascular dis-
ease (www.heartstats.org). General practitioners need
an accurate and reliable tool to help them identify
patients at high risk of having a cardiovascular event.
Numerous multivariable risk scores have been devel-
oped to estimate a patient’s 10 year risk of cardio-
vascular disease based on certain key known risk
factors,
12 including the Framingham risk score
3 and
the Reynoldsrisk score,
4 bothdevelopedusingpatient
data from US, the SCORE system using patients from
multiple European countries,
5 and ASSIGN using
patients from Scotland.
6 In the United Kingdom,
until recently the National Institute for Health and
Clinical Excellence (NICE) recommended use of the
long established Framingham equation to inform a
patient treatment plan about cardiovascular risk.
3
NICE have now ceased recommending any single
risk score equation, leaving healthcare professionals
to choose the tool they consider to be most
appropriate.
7
The QRISK1 risk score, derived by the QRE-
SEARCH organisation of the University of Notting-
ham, is a model to predict the 10 year risk of
developing cardiovascular disease. It was developed
8
and validated
910 on large general practice databases
in the United Kingdom using data from three million
patients with 17.5 million person years of observation.
QRISK1 includes traditional risk factors such as age,
sex, systolic blood pressure, smoking status, and total
serum cholesterol:high density lipoprotein ratio that
areincludedinthelongestablishedFraminghamequa-
tions, but it also includes body mass index, family his-
tory of cardiovascular disease, social deprivation
(Townsend score), and use of antihypertensive treat-
ment. Performance data comparing QRISK1 with the
Framingham equation indicated that QRISK1 is a
more accurate tool to predict the development of
cardiovascular disease in the United Kingdom.
911
QRISK2, the successor to QRISK1, is a new multi-
variable risk score that contains all the risk factors that
areinQRISK1butalsoincludesselfassignedethnicity
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(includingdiagnosedtype2diabetes,treatedhyperten-
sion, rheumatoid arthritis, renal disease, and atrial
fibrillation).
12 QRISK2 also contains interactions
between age and Townsend score, body mass index,
systolicbloodpressure,familyhistory,smokingstatus,
treated hypertension, diagnosisof type 2 diabetes, and
atrial fibrillation (see box for variables included in
QRISK1, QRISK2 and NICE Framingham). All con-
tinuous risk factors were carefully handled and kept
continuous throughout the model building process,
fractional polynomials were used to model nonlinear
risk relations where appropriate.
13 Technical details of
the actual QRISK2 model can be found on the QRE-
SEARCH website (www.qresearch.org).
After the development of a new multivariable risk
score, it needs to be subjected to external
validation.
1415 The performance of a risk score is typi-
callyoverestimatedintheoriginaldatausedtodevelop
the score.
14 External validation is a crucial step to pro-
vide sufficient evidence about the performance of the
risk score on a cohort not used in the score’s
development.
214-16 It is disappointing, however, that
most risk scores that are published fail to undergo this
extrastep.Studiesthatdevelopandvalidateriskscores
are far too often of low quality, poorly designed, use
inappropriate statistical techniques, and are based on
small selective cohorts with insufficient numbers of
events.
141517-19 Furthermore, it is likely that many of
the risk scores published each year are opportunisti-
cally produced to maximise the output from a clinical
study for which developing a risk score was not
declared a priori before collecting the data.
20 Guiding
efficient clinical decision making requires that the
assessment of risk be accurate, yet many risk scores in
use have not adequately shown this essential quality.
Low quality risk scores may be used clinically to stra-
tify patients into risk groups or as inclusion or exclu-
sion criteria for randomised controlled trials.
This article describes the results from an indepen-
dentandexternalvalidationofQRISK2andcompares
the performance of QRISK2 against QRISK1
8 and an
adjusted version of the Framingham equation
3 pre-
viously recommended by NICE.
21
METHODS
Study population
Study participants were patients registered between
1 January 1993 and 20 June 2008 and recorded on
the THIN database (www.thin-uk.com). Patients were
excludediftheyhadapriordiagnosisofcardiovascular
disease, had invalid dates or invalid recorded risk fac-
torvaluesoutofplausiblerange,were undertheageof
35 years, were aged 74 years or over, had missing
Townsend scores (social deprivation), or were pre-
scribed statins at baseline.
Cardiovascular disease outcomes
The primary outcome measure was the first diagnosis
of cardiovascular disease (myocardial infarction,
angina, coronary heart disease, stroke, and transient
Summary of risk factors in QRISK1, QRISK2, and Framingham equation
QRISK1
Age (continuous)
Ratio of total serum cholesterol:high density lipoprotein (continuous)
Systolic blood pressure (continuous)
Smoking status (current smoker/non-smoker (including former smoker))
Body mass index (continuous)
Family history of coronary heart disease in first degree relative under 60 years (yes/no)
Townsend deprivation score (output area level 2001 census data evaluated as continuous
variable)
Receiving treatment for blood pressure at baseline (at least one current prescription of at
least one antihypertensive agent) (yes/no)
Systolic blood pressure × Receiving treatment for blood pressure at baseline
QRISK2
Age (continuous)
Ratio of total serum cholesterol:high density lipoprotein (continuous)
Systolic blood pressure (continuous)
Smoking status (current smoker/non-smoker (including former smoker))
Body mass index (continuous)
Family history of coronary heart disease in first degree relative under 60 years (yes/no)
Townsend deprivation score (output area level 2001 census data evaluated as continuous
variable)
Treated hypertension (diagnosis of hypertension and at least one current prescription of at
least one antihypertensive agent) (yes/no)
Self assigned ethnicity (white (or not recorded)/Indian/Pakistani/Bangladeshi/other
Asian/black African/black Caribbean/other (including mixed))
Type 2 diabetes (yes/no)
Rheumatoid arthritis (yes/no)
Atrial fibrillation (yes/no)
Renal disease (yes/no)
Age × body mass index
Age × Townsend score
Age × systolic blood pressure
Age × family history of cardiovascular disease
Age × smoking current
Age × treated hypertension
Age × type 2 diabetes
Age × atrial fibrillation
Framingham equation (version recommended by NICE)
Age (continuous)
Ratio of total serum cholesterol/high density lipoprotein (continuous)
Systolic blood pressure (continuous)
Smoking status (current smoker (or quit within last year)/non-smoker)
Sex (male/female)
Left ventricular hypertrophy (yes/no)
Type 2 diabetes (yes/no)
Age × type 2 diabetes
Left ventricular hypertrophy × age
Age × sex
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Statistical analysis
Ten-year estimated cardiovascular disease risk for
every patient in the THIN cohort was calculated
using QRISK2. Observed 10-year cardiovascular dis-
ease risks were obtained using the method of Kaplan-
Meier. Multiple imputation was used to replace miss-
ing values for body mass index, systolic blood pres-
sure, total serum cholesterol:high density lipoprotein
ratio, and smoking status. Multiple imputation is a
powerful technique that offers substantial improve-
ments over the biased and flawed value replacement
approaches based on complete cases or cases matched
forageandsex.
2223Itinvolvescreatingmultiplecopies
of the data and imputing the missing values with sen-
sible values randomly selected from their predicted
distribution. We used the MICE (Multivariate Imputa-
tion by Chained Equations) library in R software to
create 20 imputed datasets and then combined the
results from analyses on each of the imputed datasets
to produce estimates and confidence intervals that
incorporate the uncertainty of imputed values.
Predictive performance of QRISK2 for the THIN
cohortwasassessedbyexaminingmeasuresofcalibra-
tion and discrimination. Calibration refers to how clo-
selythepredicted10yearriskofcardiovasculardisease
agrees with the observed 10 year risk. This was
assessed for each tenth of predicted risk, ensuring 10
equally sized groups, and for each 5 year age band by
calculating the ratio of predicted to observed risk of
cardiovascular disease separately for men and for
women. Calibration of the risk score predictions was
assessed by plotting observed proportions versus pre-
dicted probabilities. The Brier score for censored sur-
vival data was also calculated,
24 which is a measure of
accuracyandistheaveragesquareddeviationbetween
predicted and observed risk; a lower score represents
higher accuracy.
Discrimination is the ability of the risk score to dif-
ferentiate between patients who experience a cardio-
vascular event during the study and those who do
not. This measure is quantified by calculating the area
under the receiver operating characteristics curve
(AUROC) statistic; a value of 0.5 represents chance,
and1representsperfectdiscrimination.Wealsocalcu-
latedtheDstatistic
25andR
2statistic
26(derivedfromthe
D statistic), which are measures of discrimination and
explained variation respectively and are tailored
towards censored survival data. Higher values of D
indicate greater discrimination, where an increase of
0.1 over other risk scores is a good indicator of
improved prognostic separation. Scaled rectangular
diagrams are presented to illustrate the discrimination
performance of QRISK2 and NICE Framingham.
27
Although predicted risk varies across a continuum,
clinical decisions require creation of risk groups. An
important aspect, therefore, when considering adopt-
ing a new risk prediction rule is the classification of
patients into high and low risk and the number of
patients who would be reclassified to a different risk
category when compared with the standard means of
risk prediction
28 (here the NICE Framingham equa-
tion). Patients were identified as high risk if their
10 year predicted cardiovascular disease risk was
≥20%, as per the guidelines set out by NICE.
21
We compared the performance of QRISK2 with its
predecessor QRISK1
8 and with a modified version of
the Framingham equation
3 recommended by NICE.
Thereisanincreasedriskofdevelopingcardiovascular
disease in people with a family history of premature
disease, and risk varies between ethnic groups in the
United Kingdom. Until recently, the approach recom-
mended by NICE was to apply adjustment factors to
Table 1 |Characteristics of patients from THIN database who were included in study. Values
are numbers (percentages) unless stated otherwise
Women Men
Total patients 797 373 (50.37) 785 733 (49.63)
Total person years of observation 4 832 294 4 567 097
Median (IQR) age (years) 49 (41-59) 48 (40-57)
Country:
England 688 015 (86.29) 678 375 (86.34)
Scotland 43 276 (2.77) 42 471 (5.41)
Wales 44 033 (5.43) 44 065 (5.61)
Northern Ireland 22 049 (5.52) 20 822 (2.65)
Ethnicity:
White or not recorded 780 117 (97.84) 769 409 (97.92)
Indian 4007 (0.50) 3928 (0.50)
Pakistani 1138 (0.15) 1181 (0.15)
Bangladeshi 356 (0.04) 447 (0.06)
Other Asian 1953 (0.24) 1900 (0.24)
Black Caribbean 2270 (0.28) 1762 (0.22)
Black African 2921 (0.37) 2728 (0.35)
Chinese 782 (0.10) 615 (0.08)
Other including mixed 3829 (0.48) 3763 (0.48)
Mean (SD) systolic blood pressure (mm HG) 131.54 (20.73) 135.22 (19.01)
Mean (SD) total serum cholesterol
concentration (mmol/l)
5.76 (1.16) 5.58 (1.12)
Mean (SD) HDL cholesterol (mmol/l) 1.58 (0.43) 1.31 (0.35)
Mean (SD) total serum cholesterol:HDL ratio 3.91 (1.25) 4.54 (1.38)
Mean (SD) body mass index (kg/m
2) 26.27 (4.99) 26.71 (4.11)
Positivefamilyhistoryofcoronaryheartdisease 38 562 (4.84) 31 744 (4.04)
Current smoker 180 774 (22.67) 215 650 (27.45)
Treated hypertension 50 758 (6.37) 37 529 (4.78)
Type 2 diabetes 13 800 (1.73) 18 470 (2.35)
Rheumatoid arthritis 8479 (1.06) 3555 (0.45)
Atrial fibrillation 3035 (0.38) 4937 (0.63)
Chronic kidney disease 1187 (0.15) 1087 (0.14)
Deprivation index (Townsend score) fifth:
1 (most affluent) 219 287 (27.50) 212 487 (27.04)
2 183 335 (22.99) 175 250 (22.30)
3 165 391 (20.74) 161 349 (20.53)
4 138 226 (17.34) 138 201 (17.59)
5 (most deprived) 91 134 (11.43) 98 446 (12.53)
Incident CVD events in 10 years 29 057 (3.64) 42 408 (5.4)
Observed 10 year risk (95% CI) of CVD events 5.89 (5.81 to 5.96) 9.00 (8.90 to 9.10)
HDL=high density lipoprotein. CVD=cardiovascular disease.
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 3 of 9the Framingham equation for ethnicity and family his-
tory, which are not captured in the Framingham equa-
tion. The Framingham score is multiplied by 1.4 for
South Asian men (no adjustment for South Asian
women) and by 1.5 for people with a history of coron-
ary heart disease in a first degree relative. For South
Asian men with a family history of coronary heart dis-
easeinafirstrelative,bothadjustmentsareapplied.To
date there has been no detailed published scientific
evaluation and validation for the choice of adjustment
factor.
All statistical analyses were carried out in R (version
2.9.1).
29
RESULTS
TheTHINdatabasesystemincluded3587306eligible
patients registeredat 382 practices in the United King-
dom.Aftersequentiallyexcluding,aspertheexclusion
criteria, 625454 patients who left the general practice
before 1 January 1993, 1107612 aged <35 years or
≥74 years, 161746 with missing Townsend scores,
86693withapriordiagnosisofcardiovasculardisease,
and 23019 with prior statin use, the analysed cohort
consisted of 1583106 patients registered between
1 January 1993 and 20 June 2008 at 365 general
practices. The median follow-up was 6.2 years, and
241859 (15.28%) patients were followed for at least
10years.The10yearobservedriskofacardiovascular
event in men aged 35-74 years was 9.00% (95% confi-
dence interval 8.90% to 9.10%) and in women was
5.89% (5.81% to 5.96%). Table 1 details the character-
istics of eligible patients.
Completedataforallriskfactors(ratiooftotalserum
cholesteroltohighdensitylipoproteincholesterol,sys-
tolic blood pressure, body mass index, and smoking
status) considered were available for 18.4% of women
(n=146651) and 16.0% of men (n=125978). Most
patients (n=1066926 (67.4%)) had none or only one
missing risk factor. There were markedly high levels
of missing data for the total serum cholesterol:high
density lipoprotein ratio (74.7% for women and
74.6% for men). For other risk factors, the levels of
missing data were, for body mass index, 19.4% for
women, 28.5% for men; for systolic blood pressure,
7.4% for women, 16.5% for men; and for smoking sta-
tus, 20.1% for women, 29.2% for men.
Table 2 shows the incidence rates (per 1000 person
years) for cardiovascular disease by age, sex, region of
UK, ethnicity, and deprivation index. In total there
were 71465 incident cases of cardiovascular disease
Table 2 |Crude and age adjusted incidence rates (per 1000 person years) for cardiovascular disease by sex, age, country, ethnicity, and social deprivation
Women Men
Total
person
years
No of
incident
cases
Crude incidence rate
(95% CI)
Age standardised
rates (95% CI)
Total
person
years
No of
incident
cases
Crude incidence rate
(95% CI)
Age standardised
rates (95% CI)
Total 4 832 294 29 057 6.01 (5.94 to 6.08) — 4 567 097 42 408 9.29 (9.20 to 9.37) —
Age (years):
35-44 1 664 619 1965 1.18 (1.13 to 1.23) — 1 718 707 3999 2.33 (2.26 to 2.40) —
45-54 1 414 936 5029 3.55 (3.46 to 3.65) — 1 396 812 10 013 7.17 (7.03 to 7.31) —
55-64 1 033 376 8936 8.65 (8.47 to 8.83) — 924 993 14 284 15.44(15.19to15.70) —
65-74 719 363 13 127 18.25(17.94to18.56) — 526 585 14 112 26.80(26.36to27.24) —
Country:
England 4 168 032 24 501 5.88 (5.80 to 5.95) 5.75 (5.68 to 5.82) 3 943 200 36 125 9.16 (9.07 to 9.26) 9.06 (8.97 to 9.16)
Scotland 265 125.6 2026 7.64 (7.31 to 7.98) 7.97 (7.63 to 8.33) 248 023 2652 10.69(10.29to11.11) 11.15 (10.73 to 11.59)
Wales 258 111.9 1613 6.25 (5.95 to 6.56) 6.11 (5.81 to 6.41) 247 922 2346 9.46 (9.08 to 9.85) 9.21 (8.84 to 9.59)
Northern Ireland 141 025.1 917 6.50 (6.09 to 6.94) 6.77 (6.33 to 7.22) 127 951 1285 10.40 (9.50 to 10.61) 10.42 (9.85 to 11.01)
Ethnic group:
Whiteornotrecorded 4 766 861 28 625 6.00 (5.94 to 6.07) 5.89 (5.82 to 5.96) 4 509 833 41 856 9.28 (9.19 to 9.37) 9.20 (9.11 to 9.29)
Indian 19 175 150 7.82 (6.62 to 9.18) 9.33 (7.86 to 10.99) 16 915 219 12.95(11.29to14.78) 13.62 (11.87 to 15.56)
Pakistani 4376 45 10.28 (7.50 to 13.76) 13.22 (9.47 to 17.95) 3936 68 17.28(13.42to21.90) 19.55 (15.04 to 24.99)
Bangladeshi 1236 11 8.90 (4.44 to 15.92) 8.66 (4.30 to 15.57) 1326 16 12.07 (6.89 to 19.60) 16.81 (9.43 to 27.67)
Other Asian 6311 35 5.55 (3.86 to 7.71) 6.67 (4.58 to 9.38) 5745 64 11.14 (8.58 to 14.23) 13.89 (10.60 to 17.90)
Black Caribbean 11 238 90 8.01 (6.44 to 9.84) 8.94 (7.16 to 11.02) 8150 64 7.85 (6.05 to 10.03) 6.93 (5.31 to 8.88)
Black African 8102 20 2.47 (1.51 to 3.81) 4.26 (2.55 to 6.69) 7476 22 2.94 (1.84 to 4.46) 4.44 (2.66 to 6.96)
Chinese 2399 9 3.75 (1.71 to 7.12) 6.41 (2.75 to 12.68) 1787 10 5.60 (2.68 to 10.29) 6.42 (3.05 to 11.88)
Other 12 596 72 5.72 (4.47 to 7.20) 7.33 (5.69 to 9.28) 11 929 89 7.46 (5.99 to 9.18) 8.94 (7.14 to 11.05)
Deprivation index
(Townsend score) fifth:
1 (most affluent) 1 387 251 6078 4.38 (4.27 to 4.49) 4.52 (4.41 to 4.64) 1 303 775 10 334 7.93 (7.77 to 8.08) 7.84 (7.69 to 7.99)
2 1 140 383 6168 5.41 (5.27 to 5.55) 5.23 (5.10 to 5.37) 1 053 009 9542 9.06 (8.88 to 9.25) 8.65 (8.48 to 8.83)
3 999 210 6183 6.19 (6.03 to 6.34) 6.04 (5.89 to 6.20) 934 476 8851 9.47 (9.28 to 9.67) 9.48 (9.29 to 9.68)
4 801 680 6060 7.56 (7.37 to 7.75) 7.30 (7.11 to 7.48) 762 139 7841 10.29(10.06to10.52) 10.40 (10.18 to 10.64)
5 (most deprived) 503 770 4568 9.07 (8.81 to 9.33) 8.81 (8.55 to 9.07) 513 698 5840 11.37(11.08to11.66) 11.82 (11.52 to 12.13)
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of observation. The age adjusted incidence rate (per
1000 person years) for cardiovascular disease was
highest in Scottish women and men (7.97 and 12.04)
andlowestinEnglishwomenandmen(5.75and9.89).
The incidence of cardiovascular disease varied
widely between different ethnic groups. The age stan-
dardised rates (per 1000 person years) for the white
reference group were 5.89 for women and 9.20 for
men. The highest rates were among the South Asian
groups—for example, in Pakistani women the rate
was 13.22 (per 1000 person years) and in Pakistani
men it was 19.55.
Discrimination and calibration
For an accurate risk score the predicted and observed
risks will agree. Fig 1 shows calibration plots for the
three risk scores. Both QRISK2 and its predecessor,
QRISK1, show much better agreement between
observed risk and predicted risk grouped by tenth of
risk compared with the NICE adjusted Framingham
equation.
Table 3presentsdiscriminationandcalibrationper-
formance data for QRISK2, QRISK1, and the NICE
adjusted Framingham equation. The R
2 statistic (per-
centage of explained variation) is approximately 5%
higherforQRISK2inbothmenandwomencompared
with the NICE adjusted Framingham equation. The
difference in R
2 between QRISK2 and QRISK1 is
less pronounced, with QRISK2 explaining around
only 1% more of the variation in outcome in both
men and women. The D discrimination statistic,
where a higher score represents better discrimination,
is higher for QRISK2 in both men and women com-
pared with the NICE adjusted Framingham equation.
As with the R
2 statistic, the difference in the D statistics
between QRISK2 and QRISK1 is small. The Brier
score (adjusted for censoring), a measure of prediction
accuracy, was lower for QRISK2 in both men and
women compared with the NICE adjusted Framing-
ham equation. There was no difference between
QRISK2 and QRISK1 in Brier score (0.076).
Risk classification
Usinga 20% thresholdforhighriskof havinga cardio-
vascular event, we calculated how many patients
would be reclassified from low risk to high risk (and
vice versa) using QRISK2 compared with the NICE
adjusted version of Framingham.
In total, 90823 male patients (11.6%) would be
reclassified, with 1.8% (11231) upgraded from low
risk with NICE Framingham to high risk with
QRISK2 (table 4). The observed risk in these patients
was 20.02% (95% confidence interval 16.98% to
23.06%). The average predicted risk with the NICE
Framingham equation was 14.73% whereas it was
24.08% with QRISK2. Nearly half the patients
assessed as high risk with NICE Framingham (79592
(45%)) would be downgraded to low risk with
QRISK2. The observed risk in these patients was
14.00% (12.28% to 15.72%), compared with a mean
predicted risk of 25.14% with NICE Framingham and
14.98% with QRISK2.
Similarly, 41126 female patients (5.2%) would be
reclassified, with 15748 upgraded from low risk with
NICEFraminghamtohighriskwithQRISK2(table 5).
The mean observed risk in these patients was 20.07%
(18.84% to 21.30%). The average predicted risk with
the NICE Framingham equation was 15.19% and
with QRISK2 was 23.70%. Likewise, 25478 patients
would be downgraded from high risk with NICE Fra-
mingham to low risk with QRISK2, with a mean
observed risk of 13.36% (10.72% to 16.00%). The cor-
responding mean predicted risk was 24.24% with
NICE Framingham and 15.32% with QRISK2.
Table 3 |Discrimination and model performance statistics for QRISK2, QRISK1, and NICE
Framingham (version of the Framingham equation recommended by NICE) in estimating 10-
year risk of a cardiovascular event in the THIN cohort
QRISK2 QRISK1 NICE Framingham
Women
AUROC statistic 0.801 0.799 0.774
D statistic (95% CI) 1.66 (1.56 to 1.76) 1.61 (1.50 to 1.71) 1.47 (1.29 to 1.64)
R
2 statistic (95% CI) 39.5 (36.6 to 42.4) 38.2 (35.1 to 41.3) 33.8 (28.5 to 39.2)
Brier score* (95% CI) 0.052 (0.050 to 0.054) 0.052 (0.050 to 0.054) 0.054 (0.051 to 0.057)
Men
AUROC statistic 0.773 0.771 0.750
D statistic (95% CI) 1.45 (1.31 to 1.59) 1.42 (1.28 to 1.55) 1.30 (1.12 to 1.48)
R
2 statistic (95% CI) 33.3 (28.9 to 37.8) 32.3 (28.3 to 36.4) 28.7 (23.1 to 34.3)
Brier score* (95% CI) 0.076 (0.074 to 0.078) 0.076 (0.074 to 0.079) 0.082 (0.079 to 0.085)
AUROC = area under the receiver operating characteristics curve.
*Lower score indicates better accuracy of risk estimates.
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Fig 1 | Plot of observed versus predicted risks of cardiovascular
disease for QRISK2, QRISK1, and the NICE adjusted
Framingham equation.
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risks in patients reclassified from high to low risk (and
vice versa) with QRISK2 were more accurate com-
pared with the mean observed risk than mean pre-
dicted risks with NICE Framingham (see online
appendix for low, intermediate, and high risk classifi-
cation). Those patients who were reclassified as high
risk with QRISK2 from low risk with NICE Framing-
ham tended to be older, have been treated for hyper-
tension, have a family history of coronary heart
disease, and have a diagnosis of type 2 diabetes, rheu-
matoid arthritis, or atrial fibrillation.
Theproportionofmenandwomenclassifiedashigh
risk by QRISK2 and NICE Framingham who had a
subsequent cardiovascular event are displayed in
fig 2, a scaled rectangular diagram. At current recom-
mendedtreatment thresholds of 20%, the figure shows
the modest discrimination performance of both
QRISK2 and the NICE Framingham model. With
QRISK2, 14% of the male cohort would be identified
as being at high risk and would capture 40% of the
cardiovascular events; NICE Framingham would
identify 22%of the malecohort and 54%of the cardio-
vascularevents.Similarly,forwomen,QRISK2would
identify 6% of the cohort as being at high risk and 26%
of the cardiovascular events, whereas NICE Framing-
ham would identify 7% of the cohort as high risk and
26% of all cardiovascular events.
Incidence of cardiovascular events in high risk groups
Using the 20% threshold to identify high risk patients,
QRISK2 identified a group of patients at a higher risk
of cardiovascular events than those identified with
NICE Framingham. The incidence rate of cardio-
vascular events among men designated high risk with
QRISK2 was 27.8 per 1000 person years (95% confi-
dence interval 27.4 to 28.2), whereas it was 21.9 (21.6
to 22.2) with NICE Framingham and 24.8 (22.8 to
26.9) with QRISK1. For women, the incidence rate of
cardiovasculareventsinthosedesignatedhighriskwas
24.3 (23.8 to 24.9) with QRISK2, 20.6 (20.1 to 21.0)
with NICE Framingham, and 21.8 (18.9 to 24.6) with
QRISK1.Table 6showsregionalvariationsintheinci-
dence of cardiovascular events in high risk groups.
DISCUSSION
Principal findings
We independently evaluated the performance of the
QRISK2riskscore,incomparisonwiththeriskpredic-
tion approach (NICE Framingham) that was until
recently recommended by the National Institute for
Health and Clinical Excellence in the United King-
dom, for predicting 10-year cardiovascular disease in
Table 4 |Comparison of QRISK2 and NICE Framingham (version of the Framingham equation recommended by NICE) in
classification of men in the THIN cohort into low or high 10-year risk of cardiovascular events and observed and predicted
risk
QRISK2
Total No (%) of men reclassified Low risk (<20%) High risk (≥20%)
NICE Framingham, low risk (<20%)
No (range) of men 599179(581620-617650) 11 231 (10 311–12 409) 610410(592304–630059)
11 231 (1.8)
No (range) of events 18 258 (16 692–19 744) 1335 (1148–1507) 19 593 (17 845–21 251)
Observed risk (95% CI) 5.32 (4.82 to 5.81) 20.02 (16.98 to 23.06) 5.57 (5.04 to 6.11)
Mean risk QRISK2 (95% CI) 5.28 (5.23 to 5.34) 24.08 (23.72 to 24.44) 5.62 (5.54 to 5.72)
Mean risk NICE (95% CI) 8.64 (8.39 to 8.90) 14.73 (14.35 to 15.11) 8.76 (8.50 to 9.01)
NICE Framingham, high risk (≥ ≥20%)
No (range) of men 79 592 (69 790–88 184) 95 731 (85 884–10 5245) 175323(155674–193429)
79 592 (45.4)
No (range) of events 7125 (6470–7549) 15 690 (14 410–17 014) 22 815 (21 157–24 563)
Observed risk (95% CI) 14.00 (12.28 to 15.72) 24.52 (22.74 to 26.31) 19.76 (17.97 to 21.55)
Mean risk QRISK2 (95% CI) 14.98 (14.85 to 15.11) 28.87 (28.45 to 29.29) 22.57 (22.22 to 22.92)
Mean risk NICE (95% CI) 25.14 (24.75 to 25.54) 35.47 (33.59 to 37.36) 30.79 (29.60 to 31.97)
Total
No (range) of men 678771(669804–687440) 106 962 (98 292–115 929) 785 733
90 823 (11.6)
No (range) of events 25 383 (24 241–26 491) 17 025 (15 917–18 167) 42 408
Observed risk (95% CI) 6.43 (6.12 to 6.74) 24.12 (22.68 to 25.56) 9.0 (8.9 to 9.1)
Mean risk QRISK2 (95% CI) 6.42 (6.21 to 6.63) 28.37 (27.89 to 28.85) 9.41 (8.88 to 9.94)
Mean risk NICE (95% CI) 10.58 (10.02 to 11.14) 33.30 (31.21 to 35.39) 13.68 (12.63 to 14.72)
Women Men
All women/men
QRISK2 high risk
Develop cardiovascular disease
NICE Framingham high risk
Fig 2 | Proportion of men and women classified as high 10-year
risk of cardiovascular events (≥20%) by QRISK2 and the NICE
version of the Framingham equation who also had a
subsequent cardiovascular event
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practice. In this large cohort of 1.6 million patients,
the NICE Framingham equation had inferior perfor-
mance compared with either QRISK2 or its predeces-
sor,QRISK1.TheNICEFraminghamriskscoreover-
predicted 10-year risk of cardiovascular disease, com-
pared with the more accurate QRISK2 and QRISK1
scores. The difference in performance between
QRISK2 and QRISK1 was slight, with QRISK2 mar-
ginally outperforming QRISK1. QRISK2 includes
five extra risk factors (self assigned ethnicity, type 2
diabetes, rheumatoid arthritis, atrial fibrillation, and
chronic renal disease) as well as eight interaction
terms. These additional risk factors do not require
any considerable effort to collect; ethnicity would be
recorded as white if this item were missing or not
recorded. Absence of a recorded diagnosis of type 2
diabetes, rheumatoid arthritis, atrial fibrillation, or
chronic renal disease is assumed to indicate that the
person did not have that factor.
Thedevelopmentcohort(1.5millionpatients),inter-
nal validation cohort (0.75 million patients), and this
external validation cohort (1.6 million patients)
included in total nearly 3.9 million patients (about
14% of the UK population aged between 34 and
74 years) with a total of 21 million person years of
observation and 211580 recorded cardiovascular
events. This constitutes one of the largest groups of
patients used to develop and externally validate a risk
score before its recommendation and implementation
in clinical practice, and, given the source and com-
binedsizeofallcohorts,itislikelytobeafairrepresen-
tation of the population for which the equations are to
be used.
The superior performance of the QRISK risk scores
isnotsurprisingasbothQRISKriskscoresweredevel-
oped(andinternallyandexternallyvalidated)onlarge
cohortsofgeneralpracticepatientsintheUnitedKing-
dom, the population for which the risk predictions
were targeted and designed. This includes accounting
for social deprivation,family historyof coronaryheart
disease, and ethnicity, all known to increase the risk of
developing cardiovascular disease. The Framingham
score, by contrast, was developed on a comparatively
small (n=5573), homogeneous white, though treat-
ment-naive, sample from a single town in the US
between 1968 and 1975. We evaluated the Framing-
ham risk score with the NICE designated adjustment
factors for family history and, for men, being of South
Asian origin.
Arguably, QRISK2 would be more aptly compared
with a Framingham equation recalibrated for the UK
population, but we compared it with the Framingham
risk score recommended by NICE, which is without
referencetorecalibration.Furthermore,theNICEFra-
mingham is a single equation with a sex coefficient,
whereas the QRISK approach has separate equations
for men and women. Separate equations permit risk
factors to be weighted differently for men and women.
Although some have welcomed the introduction of
the QRISK equations
3031 and the debate about
improving risk prediction, others have cautioned
against their use for two main reasons; (a) the cohort
used to develop both QRISK equations included
patients who were not treatment naive, unlike the Fra-
mingham cohort,
32 and (b) there are large amounts of
missing cholesterol data.
33 With regard to the cohorts
including patients who may have started additional
treatments, it is now neither practically nor ethically
Table 5 |Comparison of QRISK2 and NICE Framingham (version of the Framingham equation recommended by NICE) in
classification of women in the THIN cohort into low or high 10-year risk of cardiovascular events and observed and
predicted risk
QRISK2
Total
No (%) of women
reclassified Low risk (<20%) High risk (≥20%)
NICE Framingham, low risk (<20%)
No (range) of women 722367(716767–729126) 15 748 (14 802–16 926) 738115(733041–744762)
15 748 (2.1)
No (range) of events 19 242 (18 390–19 865) 2141 (2063–2260) 21 383 (20 513–21 962)
Observed risk (95% CI) 4.39 (4.15 to 4.63) 20.07 (18.84 to 21.30) 4.74 (4.51 to 4.97)
Mean risk QRISK2 (95% CI) 4.48 (4.38 to 4.58) 23.70 (23.61 to 23.79) 4.89 (4.76 to 5.03)
Mean risk NICE (95% CI) 5.56 (5.38 to 5.74) 15.19 (14.96 to 15.41) 5.76 (5.57 to 5.96)
NICE Framingham, high risk (≥ ≥20%)
No (range) of women 25 478 (22 188–28 644) 33 780 (30 423–26 205) 59 258 (52 611–64 332)
25 478 (43.0)
No (range) of events 2346 (2113–2584) 5328 (4888–6000) 7674 (7095–8544)
Observed risk (95% CI) 13.36 (10.72 to 16.00) 22.36 (18.94 to 25.78) 18.53 (15.46 to 21.60)
Mean risk QRISK2 (95% CI) 15.32 (15.15 to 15.48) 28.19 (27.79 to 28.59) 22.66 (22.05 to 23.26)
Mean risk NICE (95% CI) 24.24 (23.89 to 24.58) 30.97 (30.17 to 31.76) 28.07 (27.51 to 28.64)
Total
No (range) of women 747845(744747–751314) 49 528 (46 059–52 626) 797 373
41 126 (5.2)
No (range) of events 21 588 (20 934–22 010) 7469 (7047–8123) 29 057
Observed risk (95% CI) 4.73 (4.56 to 4.89) 21.67 (19.39 to 23.94) 5.89 (5.81 to 5.96)
Mean risk QRISK2 (95% CI) 4.85 (4.72 to 4.98) 26.76 (26.46 to 27.06) 6.21 (6.01 to 6.42)
Mean risk NICE (95% CI) 6.19 (5.95 to 6.43) 25.95 (24.98 to 26.91) 7.42 (7.10 to 7.75)
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Furthermore, although natural history is important, it
is not clear that prognosis is best assessed from an
untreated population.
Risk scores will inevitably become outdated with
improvementsinclinicaloutcomesanddatarecording
andchangesinpopulationdemographics.Thus,ensur-
ing a risk score retains its usefulness to reflect current
conditions is crucial.
34 QRISK2 will undergo annual
updates to account for changes in population charac-
teristics and improvements in data quality, with its
most recent update having been released on 1 April
2010(seewww.qrisk.orgfordetailsofthis).Thisentails
re-fitting QRISK2 to the latest version of the QRE-
SEARCH database to obtain updated regression coef-
ficients.
Strengths and weaknesses
Allthecohortsusedinthedevelopmentandvalidation
of QRISK1 and QRISK2 had high levels of missing
data for the total serum cholesterol:high density lipo-
protein ratio, so it can be assumed to be a population
feature. QRISK1 and QRISK2 were developed using
established methods of multiple imputation for miss-
ing data to address this problem. Our external valida-
tion study also used multiple imputation, with 20
imputed datasets, to deal with the missing data. We
note that problems of missing data in developing and
validating risk scores are rarely considered when vali-
dating risk scores.
35-38 Omitting patients with missing
data in developing the risk score and conducting a
complete-case analysis would introduce bias and
produce a poorly performing risk score. Even in vali-
dation, discarding missing observations will result in
performance data that is biased, and so that practice
should be avoided.
3738
Conclusions
In this study, we have provided an independent and
external validation of the QRISK2 risk score on a
large cohort of patients in the United Kingdom. We
have assessed the performance of QRISK2 against
the NICE version of the Framingham equation and
have provided evidence to support the use of
QRISK2infavouroftheNICEFraminghamequation.
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